Edgar Filing: Horizon Technology Finance Corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)


þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013

		OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 814-00802

HORIZON TECHNOLOGY FINANCE CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE		27-2114934
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

312 Farmington Avenue
Farmington, CT		06032
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (860) 676-8654

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o .

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer o	Accelerated filer þ	Non-accelerated filer o	Smaller Reporting Company o
	(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ .

As of November 5, 2013, the Registrant had 9,592,875 shares of common stock, $0.001 par value, outstanding.

HORIZON TECHNOLOGY FINANCE CORPORATION

FORM 10-Q

TABLE OF CONTENTS

		Page
	PART I

Item 1.	Consolidated Financial Statements	3

	Consolidated Statements of Assets and Liabilities as of September 30, 2013 and December 31, 2012 (unaudited)	3
	Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012 (unaudited)	4
	Consolidated Statements of Changes in Net Assets for the nine months ended September 30, 2013 and 2012 (unaudited)	5
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012 (unaudited)	6
	Consolidated Schedules of Investments as of September 30, 2013 and December 31, 2012 (unaudited)	7
	Notes to the Consolidated Financial Statements (unaudited)	15
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	32
Item 3.	Quantitative And Qualitative Disclosures About Market Risk	45
Item 4.	Controls and Procedures	45

PART II
Item 1.	Legal Proceedings	46
Item 1A.	Risk Factors	46
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	46
Item 3.	Defaults Upon Senior Securities	46
Item 4.	Mine Safety Disclosures	46
Item 5.	Other Information	46
Item 6.	Exhibits	46
	Signatures	47

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Assets and Liabilities (Unaudited)

(In thousands, except share data)

	September 30,			December 31,
	2013			2012
Assets
Non-affiliate investments at fair value (cost of $248,095 and $239,385, respectively) (Note 4)	$	241,319		$	228,613
Investment in money market funds		25,019			2,560
Cash		2,439			1,048
Restricted investments in money market funds		3,568			—
Interest receivable		4,119			2,811
Other assets		5,391			4,626
Total assets	$	281,855		$	239,658

Liabilities
Borrowings (Note 6)	$	133,000		$	89,020
Dividends payable		3,308			3,301
Base management fee payable (Note 3)		326			402
Incentive fee payable (Note 3)		872			855
Other accrued expenses		965			1,108
Total liabilities		138,471			94,686

Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2013 and December 31, 2012		—			—
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 9,588,993 and 9,567,225 shares outstanding as of September 30, 2013 and December 31, 2012, respectively		10			10
Paid-in capital in excess of par		154,696			154,384
Accumulated undistributed net investment income		1,371			1,428
Net unrealized depreciation on investments		(6,776	)		(10,772	)
Net realized loss on investments		(5,917	)		(78	)
Total net assets		143,384			144,972
Total liabilities and net assets	$	281,855		$	239,658
Net asset value per common share	$	14.95		$	15.15

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Operations (Unaudited)

(In thousands, except share data)

	For the Three Months Ended					For the Nine Months Ended
	September 30,					September 30,
	2013			2012		2013			2012
Investment income
Interest income on non-affiliate investments	$	8,225		$	6,426	$	23,979		$	17,803
Fee income on non-affiliate investments		487			193		889			923
Total investment income		8,712			6,619		24,868			18,726
Expenses
Interest expense		2,189			1,089		5,886			2,754
Base management fee (Note 3)		1,266			1,087		3,836			3,042
Performance based incentive fee (Note 3)		872			742		2,465			1,992
Administrative fee (Note 3)		287			352		889			854
Professional fees		284			147		977			746
General and administrative		247			233		793			758
Total expenses		5,145			3,650		14,846			10,146
Net investment income before excise tax		3,567			2,969		10,022			8,580
Provision for excise tax		(80	)		—		(160	)		—
Net investment income		3,487			2,969		9,862			8,580
Net realized and unrealized (loss) gain on investments
Net realized loss on investments		(5,566	)		—		(5,839	)		(61	)
Net unrealized appreciation (depreciation) on investments		5,967			677		3,996			(117	)
Net realized and unrealized gain (loss) on investments		401			677		(1,843	)		(178	)
Net increase in net assets resulting from operations	$	3,888		$	3,646	$	8,019		$	8,402
Net investment income per common share	$	0.36		$	0.33	$	1.03		$	1.06
Net increase in net assets per common share	$	0.41		$	0.40	$	0.84		$	1.03
Dividends declared per share	$	0.345		$	0.45	$	1.035		$	1.35
Weighted average shares outstanding		9,584,376			9,078,010		9,577,912			8,121,986

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Changes in Net Assets (Unaudited)

(In thousands, except share data)

			Common		Paid-In Capital in Excess of		Accumulated Undistributed Net Investment			Net Unrealized Depreciation on			Net Realized Gains (Losses) on			Total Net
	Shares		Stock		Par		Income			Investments			Investments			Assets
Balance at December 31, 2011		7,636,532	$	8	$	124,512	$	4,965		$	(2,659	)	$	3,058		$	129,884
Issuance of common stock (net of offering costs) ⁽¹⁾		1,909,000		2		29,543		—			—			—			29,545
Net increase in net assets resulting from operations		—		—		—		8,580			(117	)		(61	)		8,402
Issuance of common stock under dividend reinvestment plan		17,424		—		288		—			—			—			288
Dividends declared		—		—		—		(11,173	)		—			—			(11,173	)
Balance at September 30, 2012		9,562,956	$	10	$	154,343	$	2,372		$	(2,776	)	$	2,997		$	156,946

Balance at December 31, 2012		9,567,225	$	10	$	154,384	$	1,428		$	(10,772	)	$	(78	)	$	144,972
Net increase in net assets resulting from operations		—		—		—		9,862			3,996			(5,839	)		8,019
Issuance of common stock under dividend reinvestment plan		21,768		—		312		—			—			—			312
Dividends declared		—		—		—		(9,919	)		—			—			(9,919	)
Balance at September 30, 2013		9,588,993	$	10	$	154,696	$	1,371		$	(6,776	)	$	(5,917	)	$	143,384

⁽¹⁾

On July 18, 2012, the Company completed a follow-on public offering of 1,909,000 shares (including 249,000 shares of common stock that were issued pursuant to the underwriters’ option to purchase additional shares) of its common stock at a public offering price of $16.20 per share. Total offering costs were $1.4 million.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

	For the Nine Months Ended
	September 30,
	2013			2012
Cash flows from operating activities:
Net increase in net assets resulting from operations	$	8,019		$	8,402
Adjustments to reconcile net increase in net assets resulting from operations to net cash used in operating activities:
Amortization of debt issuance costs		902			286
Net realized loss on investments		5,629			61
Net unrealized (appreciation) depreciation on investments		(3,996	)		117
Purchase of investments		(69,143	)		(86,720	)
Principal payments received on investments		55,954			44,186
Proceeds from sale on investments		39			38
Changes in assets and liabilities:
Net (increase) decrease in investments in money market funds		(22,459	)		11,152
Net increase in restricted investments in money market funds		(3,568	)		—
Increase in interest receivable		(160	)		(70	)
Increase in end-of-term payments		(1,148	)		(1,011	)
Decrease in unearned loan income		(1,190	)		(578	)
Decrease in other assets		458			16
Decrease in other accrued expenses		(143	)		(260	)
(Decrease) increase in base management fee payable		(76	)		62
Increase (decrease) in incentive fee payable		17			(1,024	)
Net cash used in operating activities		(30,865	)		(25,343	)

Cash flows from financing activities:
Proceeds from issuance of 2019 Notes		—			33,000
Proceeds from shares sold, net of offering cost		—			29,545
Proceeds from issuance of Asset-Backed Notes		90,000			—
Dividends paid		(9,599	)		(10,885	)
Net decrease in Credit Facilities		(46,020	)		(21,320	)
Debt issuance costs		(2,125	)		(3,007	)
Net cash provided by financing activities		32,256			27,333
Net increase in cash		1,391			1,990

Cash:
Beginning of period		1,048			1,298
End of period	$	2,439		$	3,288
Supplemental disclosure of cash flow information:
Cash paid for interest	$	4,982		$	2,395
Supplemental non-cash investing and financing activities:
Warrant investments received & recorded as unearned loan income	$	626		$	1,120
Dividends Payable	$	3,308		$	—

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

September 30, 2013

(In thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount		Investments (6)		Value
Debt Investments — 161.6% (9)
Debt Investments — Life Science — 29.3% (9)
ACT Biotech Corporation (8)	Biotechnology	Term Loan (13.10% cash, 8.00% ETP, Due 9/1/14)	$	3,947	$	3,905	$	2,677
Celsion Corporation (2)(5)	Biotechnology	Term Loan (11.75% cash, Due 10/1/15)		2,132		2,121		2,121
Inotek Pharmaceuticals Corporation (2)	Biotechnology	Term Loan (11.00% cash, 3.00% ETP, Due 10/1/16)		3,500		3,454		3,454
N30 Pharmaceuticals, LLC (2)	Biotechnology	Term Loan (11.25% cash, 3.00% ETP, Due 9/1/14)		999		992		992
		Term Loan (11.25% cash, 3.00% ETP, Due 10/1/15)		2,500		2,473		2,473
New Haven Pharmaceuticals, Inc. (2)	Biotechnology	Term Loan (11.50% cash, 3.00% ETP, Due 5/1/16)		1,500		1,471		1,471
		Term Loan (11.50% cash, 3.00% ETP, Due 5/1/16)		500		490		490
Sample6, Inc. (2)	Biotechnology	Term Loan (11.00% cash, 3.00% ETP, Due 1/1/16)		2,500		2,472		2,472
Sunesis Pharmaceuticals, Inc. (2)(5)	Biotechnology	Term Loan (8.95% cash, 3.75% ETP, Due 10/1/15)		1,602		1,593		1,593
		Term Loan (9.00% cash, 3.75% ETP, Due 10/1/15)		2,404		2,355		2,355
Xcovery Holding Company, LLC (2)	Biotechnology	Term Loan (12.50% cash, Due 8/1/15)		884		883		883
		Term Loan (12.50% cash, Due 8/1/15)		1,391		1,388		1,388
		Term Loan (12.50% cash, Due 10/1/15)		250		249		249
Direct Flow Medical, Inc. (2)	Medical Device	Term Loan (11.00% cash, 3.00% ETP, Due 7/1/16)		5,000		4,923		4,923
		Term Loan (11.00% cash, 3.00% ETP, Due 10/1/16)		2,500		2,456		2,456
Mitralign, Inc. (2)	Medical Device	Term Loan (12.00% cash, 3.00% ETP, Due 10/1/15)		1,714		1,695		1,695
		Term Loan (10.88% cash, 3.00% ETP, Due 11/1/15)		1,143		1,129		1,129
		Term Loan (10.50% cash, 3.00% ETP, Due 7/1/16)		1,143		1,110		1,110
PixelOptics, Inc. (2)(8)	Medical Device	Term Loan (10.75% cash, 3.00% ETP, Due 11/1/14)		5,000		4,985		2,798
Tengion, Inc. (2)(5)	Medical Device	Term Loan (13.00% cash, Due 5/1/14)		2,379		2,355		2,355
Tryton Medical, Inc.	Medical Device	Term Loan (10.41% cash, 2.50% ETP, Due 9/1/16)		3,000		2,957		2,957
Total Debt Investments — Life Science						45,456		42,041
Debt Investments — Technology — 94.3% (9)
Avalanche Technology, Inc. (2)	Semiconductors	Term Loan (10.00% cash, 2.00% ETP, Due 7/1/16)		3,256		3,176		3,176
eASIC Corporation	Semiconductors	Term Loan (11.00% cash, 2.50% ETP, Due 4/1/17)		2,000		1,964		1,964
Kaminario, Inc. (2)	Semiconductors	Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16)		3,000		2,947		2,947
		Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16)		3,000		2,947		2,947
Luxtera, Inc. (2)	Semiconductors	Term Loan (10.25% cash, 8.00% ETP, Due 12/1/15)		3,038		3,013		3,013
		Term Loan (10.25% cash, 8.00% ETP, Due 3/1/16)		1,667		1,651		1,651
Newport Media, Inc. (2)	Semiconductors	Term Loan (11.00% cash, 2.14% ETP, Due 1/1/16)		3,500		3,465		3,465
		Term Loan (11.00% cash, 2.14% ETP, Due 1/1/16)		3,500		3,465		3,465
NexPlanar Corporation (2)	Semiconductors	Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16)		3,000		2,959		2,959
		Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16)		2,000		1,962		1,962
Xtera Communications, Inc. (2)	Semiconductors	Term Loan (11.50% cash, Due 3/1/15)		6,817		6,778		6,778
		Term Loan (11.50% cash, Due 10/1/15)		1,794		1,779		1,779
Ekahau, Inc.	Communications	Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)		1,500		1,439		1,439
Overture Networks, Inc. (2)	Communications	Term Loan (10.75% cash, 4.75% ETP, Due 12/1/16)		5,000		4,857		4,857
Optaros, Inc. (2)	Internet and Media	Term Loan (11.95% cash, 3.00% ETP, Due 10/1/15)		1,870		1,857		1,857
		Term Loan (11.95% cash, 3.00% ETP, Due 3/1/16)		500		496		496
SimpleTuition, Inc. (2)	Internet and Media	Term Loan (11.75% cash, Due 3/1/16)		4,284		4,226		4,226
Bolt Solutions, Inc. (2)	Software	Term Loan (11.65% cash, 4.00% ETP, Due 5/1/16)		5,000		4,956		4,956
		Term Loan (11.65% cash, 4.00% ETP, Due 5/1/16)		5,000		4,956		4,956
Construction Software Technologies, Inc. (2)	Software	Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)		4,200		4,168		4,168
		Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)		4,200		4,168		4,168
Courion Corporation (2)	Software	Term Loan (11.45% cash, Due 10/1/15)		2,984		2,973		2,973
		Term Loan (11.45% cash, Due 10/1/15)		2,984		2,973		2,973
Decisyon, Inc. (2)	Software	Term Loan (11.65% cash, 5.00% ETP, Due 9/1/16)		4,000		3,924		3,924
Fiberlink Communications Corporation (2)	Software	Term Loan (11.50% cash, 5.00% ETP, Due 7/1/16)		5,000		4,965		4,965
		Term Loan (11.50% cash, 5.00% ETP, Due 12/1/16)		3,000		2,974		2,974
Kontera Technologies, Inc. (2)	Software	Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)		4,000		3,941		3,941
		Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)		4,000		3,941		3,941
Lotame Solutions, Inc.	Software	Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)		4,000		3,966		3,966
		Term Loan (11.50% cash, 3.00% ETP, Due 9/1/19)		1,500		1,485		1,485
Netuitive, Inc. (2)	Software	Term Loan (11.75% cash, Due 1/1/16)		2,605		2,569		2,569
Raydiance, Inc. (2)	Software	Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16)		5,000		4,940		4,940
		Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16)		1,000		971		971
Razorsight Corporation (2)	Software	Term Loan (11.75% cash, 3.00% ETP, Due 11/1/16)		1,500		1,474		1,474
		Term Loan (11.75% cash, 3.00% ETP, Due 9/1/16)		1,500		1,471		1,471
Sys-Tech Solutions, Inc. (2)	Software	Term Loan (11.65% cash, Due 6/1/16)		7,400		7,188		7,188
Vidsys, Inc. (2)	Software	Term Loan (11.00% cash, 6.50% ETP, Due 6/1/16)		3,000		2,965		2,965
Visage Mobile, Inc. (2)	Software	Term Loan (12.00% cash, 3.50% ETP, Due 9/1/16)		1,000		985		985

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

September 30, 2013

(In thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount		Investments (6)		Value
Aquion Energy, Inc. (2)	Power Management	Term Loan (10.25% cash, 4.00% ETP, Due 3/1/16)		2,978		2,965		2,965
		Term Loan (10.25% cash, 4.00% ETP, Due 3/1/16)		2,978		2,965		2,965
		Term Loan (10.25% cash, 4.00% ETP, Due 6/1/16)		3,245		3,229		3,229
Xtreme Power, Inc. (2)	Power Management	Term Loan (10.75% cash, 3.50% ETP, Due 5/1/16)		6,000		5,940		5,130
Total Debt Investments — Technology						136,033		135,223
Debt Investments — Cleantech — 20.0% (9)
Renmatix, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)		2,234		2,218		2,218
		Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)		2,234		2,218		2,218
		Term Loan (10.25% cash, Due 10/1/16)		5,000		4,948		4,948
Semprius, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 2.50% ETP, Due 6/1/16)		3,481		3,457		3,457
Cereplast, Inc. (5)(8)	Waste Recycling	Term Loan (12.00% cash, Due 8/1/14)		1,129		1,027		786
		Term Loan (12.00% cash, Due 8/1/14)		1,211		1,192		843
Aurora Algae, Inc. (2)	Energy Efficiency	Term Loan (10.50% cash, 2.00% ETP, Due 5/1/15)		1,487		1,481		1,481
Rypos, Inc.	Energy Efficiency	Term Loan (11.80% cash, Due 1/1/17)		3,000		2,922		2,922
Solarbridge Technologies, Inc. (2)	Energy Efficiency	Term Loan (12.15% cash, 3.21 ETP, Due 4/1/16)		7,000		6,753		6,359
Tigo Energy, Inc. (2)	Energy Efficiency	Term Loan (13.00% cash, Due 6/1/15)		2,214		2,194		2,194
		Revolver (13.75% (Prime + 7.50%) cash, Due 12/31/13)		1,201		1,197		1,197
Total Debt Investments — Cleantech						29,607		28,623
Debt Investments — Healthcare information and services — 18.0% (9)
BioScale, Inc. (2)	Diagnostics	Term Loan (11.51% cash, Due 1/1/14)		915		914		914
Radisphere National Radiology Group, Inc. (2)	Diagnostics	Revolver (11.25% (Prime + 8.00%) cash, Due 10/1/15)		14,000		13,895		13,895
Recondo Technology, Inc. (2)	Software	Term Loan (11.50% cash, 3.00% ETP, Due 4/1/15)		1,620		1,601		1,601
		Term Loan (11.00% cash, 3.00% ETP, Due 1/1/17)		2,500		2,470		2,470
Watermark Medical, Inc. (2)	Other Healthcare	Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17)		3,500		3,447		3,447
		Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17)		3,500		3,447		3,447
Total Debt Investments — Healthcare information and services						25,774		25,774
Total Debt Investments						236,870		231,661
Warrant Investments — 4.6% (9)
Warrants — Life Science — 1.4% (9)
ACT Biotech Corporation	Biotechnology	1,521,782 Preferred Stock Warrants		—		83		—
Ambit Biosciences, Inc.(5)	Biotechnology	44,795 Common Stock Warrants		—		143		120
Anacor Pharmaceuticals, Inc. (2)(5)	Biotechnology	84,583 Common Stock Warrants		—		93		385
Celsion Corporation (5)	Biotechnology	25,685 Common Stock Warrants		—		15		—
Inotek, Pharmaceuticals Corporation	Biotechnology	114,387 Preferred Stock Warrants		—		17		17
N30 Pharmaceuticals, LLC	Biotechnology	214,200 Preferred Stock Warrants		—		122		248
New Haven Pharmaceuticals, Inc.	Biotechnology	34,729 Preferred Stock Warrants		—		22		21
Revance Therapeutics, Inc.	Biotechnology	687,091 Preferred Stock Warrants		—		223		555
Sample6, Inc.	Biotechnology	200,582 Preferred Stock Warrants		—		27		24
Sunesis Pharmaceuticals, Inc. (5)	Biotechnology	116,203 Common Stock Warrants		—		83		333
Supernus Pharmaceuticals, Inc. (2)(5)	Biotechnology	42,083 Preferred Stock Warrants		—		94		125
Tranzyme, Inc. (2)(5)	Biotechnology	77,902 Common Stock Warrants		—		6		—
Direct Flow Medical, Inc.	Medical Device	176,922 Preferred Stock Warrants		—		144		134
EnteroMedics, Inc. (5)	Medical Device	141,026 Common Stock Warrants		—		347		—
Mitralign, Inc.	Medical Device	295,238 Common Stock Warrants		—		49		38
OraMetrix, Inc. (2)	Medical Device	812,348 Preferred Stock Warrants		—		78		—
PixelOptics, Inc.	Medical Device	381,612 Preferred Stock Warrants		—		96		—
Tengion, Inc. (2)(5)	Medical Device	1,708,273 Common Stock Warrants		—		124		—
Tryton Medical, Inc.	Medical Device	47,977 Preferred Stock Warrants				14		14
ViOptix, Inc.	Medical Device	375,763 Preferred Stock Warrants		—		13		—
Total Warrants — Life Science						1,793		2,014
Warrants — Technology — 2.1% (9)
Ekahau, Inc.	Communications	978,261 Preferred Stock Warrants		—		34		34
OpenPeak, Inc.	Communications	18,997 Preferred Stock Warrants		—		89		—
Overture Networks, Inc.	Communications	344,574 Preferred Stock Warrants		—		55		55
Everyday Health, Inc.	Consumer-related Technologies	65,674 Preferred Stock Warrants		—		69		98
SnagAJob.com, Inc.	Consumer-related Technologies	365,396 Preferred Stock Warrants		—		23		269
Tagged, Inc.	Consumer-related Technologies	190,868 Preferred Stock Warrants		—		26		69
Avalanche Technology, Inc.	Semiconductors	201,835 Preferred Stock Warrants		—		45		57
eASIC Corporation`	Semi-conductor	1,877,799 Preferred Stock Warrants		—		16		16
Kaminario, Inc.	Semi-conductor	1,087,203 Preferred Stock Warrants		—		59		58
Luxtera, Inc.	Semiconductors	1,827,485 Preferred Stock Warrants		—		34		43
Newport Media, Inc.	Semiconductors	188,764 Preferred Stock Warrants		—		40		62

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

September 30, 2013

(In thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount		Investments (6)		Value
NexPlanar Corporation	Semiconductors	172,801 Preferred Stock Warrants		—		36		58
Xtera Communications, Inc.	Semiconductors	983,607 Preferred Stock Warrants		—		206		1
XIOtech, Inc.	Data Storage	2,217,979 Preferred Stock Warrants		—		22		20
Cartera Commerce, Inc.	Internet and media	90,909 Preferred Stock Warrants		—		16		160
Optaros, Inc.	Internet and media	477,403 Preferred Stock Warrants		—		21		15
SimpleTuition, Inc.	Internet and media	189,573 Preferred Stock Warrants		—		63		16
IntelePeer, Inc.	Networking	141,549 Preferred Stock Warrants		—		39		37
Motion Computing, Inc.	Networking	260,707 Preferred Stock Warrants		—		7		267
Bolt Solutions, Inc.	Software	202,892 Preferred Stock Warrants		—		113		129
Clarabridge, Inc.	Software	104,503 Preferred Stock Warrants		—		28		290
Construction Software Technologies, Inc. (2)	Software	386,415 Preferred Stock Warrants		—		69		325
Courion Corporation	Software	772,543 Preferred Stock Warrants		—		106		98
Decisyon, Inc.	Software	314,686 Preferred Stock Warrants		—		44		41
DriveCam, Inc.	Software	71,639 Preferred Stock Warrants		—		20		120
Kontera Technologies, Inc. (2)	Software	99,476 Preferred Stock Warrants		—		102		88
Lotame Solutions, Inc.	Software	216,810 Preferred Stock Warrants		—		4		4
Netuitive, Inc.	Software	748,453 Preferred Stock Warrants		—		75		56
Raydiance, Inc.	Software	735,784 Preferred Stock Warrants		—		51		52
Razorsight Corporation	Software	194,553 Preferred Stock Warrants		—		34		32
Sys-Tech Solutions, Inc.	Software	375,000 Preferred Stock Warrants		—		242		235
Vidsys, Inc.	Software	37,346 Preferred Stock Warrants		—		23		7
Visage Mobile, Inc.	Software	1,692,047 Preferred Stock Warrants		—		20		19
Aquion Energy, Inc.	Power Management	115,051 Preferred Stock Warrants		—		7		61
Xtreme Power, Inc.	Power Management	182,723 Preferred Stock Warrants		—		76		59
Total Warrants — Technology						1,914		2,951
Warrants — Cleantech — 0.5% (9)
Renmatix, Inc.	Alternative Energy	52,296 Preferred Stock Warrants		—		68		73
Semprius, Inc.	Alternative Energy	519,981 Preferred Stock Warrants		—		25		23
Cereplast, Inc. (5)	Waste Recycling	365,000 Common Stock Warrants		—		175		—
Enphase Energy, Inc. (5)	Energy Efficiency	161,959 Common Stock Warrants		—		175		353
Rypos, Inc.	Energy Efficiency	5,627 Preferred Stock Warrants		—		44		44
Solarbridge Technologies, Inc. (2)	Energy Efficiency	3,645,302 Preferred Stock Warrants		—		236		213
Tigo Energy, Inc. (2)	Energy Efficiency	804,604 Preferred Stock Warrants		—		100		28
Total Warrants — Cleantech						823		734
Warrants — Healthcare information and services — 0.6% (9)
Accumetrics, Inc.	Diagnostics	100,928 Preferred Stock Warrants		—		107		82
BioScale, Inc. (2)	Diagnostics	315,618 Preferred Stock Warrants		—		54		—
Precision Therapeutics, Inc.	Diagnostics	13,461 Preferred Stock Warrants		—		73		—
Radisphere National Radiology Group, Inc. (2)	Diagnostics	519,943 Preferred Stock Warrants		—		378		365
Recondo Technology, Inc.	Software	360,645 Preferred Stock Warrants		—		62		166
Patientkeeper, Inc.	Other Healthcare	396,410 Preferred Stock Warrants		—		269		32
Singulex, Inc.	Other Healthcare	293,632 Preferred Stock Warrants		—		44		141
Talyst, Inc.	Other Healthcare	300,360 Preferred Stock Warrants		—		100		58
Watermark Medical, Inc.	Other Healthcare	12,216 Preferred Stock Warrants		—		66		68
Total Warrants — Healthcare information and services						1,153		912
Total Warrants						5,683		6,611
Other Investments — 1.4% (9)
Vette Technology, LLC	Data Storage	Royalty Agreement Due 4/18/2019		—		4,760		2,000
Total Other Investments						4,760		2,000
Equity — 0.7% (9)
Insmed Incorporated (5)	Biotechnology	33,208 Common Stock		—		227		518
Revance Therapeutics, Inc.	Biotechnology	72,925 Preferred Stock		—		73		109
Overture Networks Inc.	Communications	386,191 Common Stock		—		482		420
Cereplast, Inc. (5)	Waste Recycling	200,000 Common Stock		—		—		—
Total Equity						782		1,047
Total Portfolio Investment Assets — 168.3% (9)					$	248,095	$	241,319

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

September 30, 2013

(In thousands)

			Principal	Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount	Investments (6)		Value
Short Term Investments — Money Market Funds — 17.4% (9)
Blackrock Liquid Fed Funds Institutional (Fund #30)				$	22,741	$	22,741
Fidelity Prime Money Market (Class I Fund #690)					91		91
US Bank Money Market					2,187		2,187
Total Short Term Investments — Money Market Funds				$	25,019	$	25,019
Short Term Investments — Restricted Investments— 2.5% (9)
US Bank Money Market (2)				$	3,568	$	3,568
Total Short Term Investments — Restricted Investments				$	3,568	$	3,568

(1)

All of the Company’s investments are in entities which are domiciled in the United States and/or have a principal place of business in the United States.

(2)

Has been pledged as collateral under the Credit Facilities or Asset-Backed Notes.

(3)

All investments are less than 5% ownership of the class and ownership of the portfolio company.

(4)

All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETP and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the loan, unless otherwise indicated. For each debt investment, the current interest rate in effect as of September 30, 2013 is provided.

(5)

Portfolio company is a public company.

(6)

For debt investments, represents principal balance less unearned income.

(7)

Preferred and common stock warrants, equity interests and other investments are non-income producing.

(8)

Debt is on non-accrual status at September 30, 2013 and is, therefore, considered non-income producing.

(9)

Value as a percent of net assets.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2012

(In thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount		Investments (6)		Value
Debt Investments — 152.0% (9)
Debt Investments — Life Science — 42.4% (9)
ACT Biotech Corporation (8)	Biotechnology	Term Loan (13.10% cash, 8.00% ETP, Due 9/1/14)	$	3,947	$	3,906	$	2,770
Ambit Biosciences Corporation (2)	Biotechnology	Term Loan (12.25% cash, 3.00% ETP, Due 10/1/13)		2,206		2,197		2,197
Anacor Pharmaceuticals, Inc. (2)(5)	Biotechnology	Term Loan (9.41% cash, 5.50% ETP, Due 4/1/15)		2,671		2,644		2,645
		Term Loan (9.67% cash, 5.50% ETP, Due 4/1/15)		2,139		2,109		2,109
		Term Loan (9.47% cash, 5.50% ETP, Due 4/1/15)		3,762		3,708		3,708
Celsion Corporation (2)(5)	Biotechnology	Term Loan (11.75% cash, Due 10/1/15)		2,500		2,466		2,466
N30 Pharmaceuticals, LLC (2)	Biotechnology	Term Loan (11.25% cash, 3.00% ETP, Due 9/1/14)		1,679		1,657		1,657
		Term Loan (11.25% cash, 3.00% ETP, Due 7/1/15)		2,500		2,450		2,450
Revance Therapeutics, Inc.	Biotechnology	Convertible Note (8.00% ETP, Due 2/10/13)		71		71		71
Sample6 Technologies, Inc. (2)	Biotechnology	Term Loan (11.00% cash, 3.00% ETP, Due 1/1/16)		2,500		2,454		2,454
Sunesis Pharmaceuticals, Inc. (2)(5)	Biotechnology	Term Loan (8.95% cash, 3.75% ETP, Due 10/1/15)		2,000		1,984		1,984
		Term Loan (9.00% cash, 3.75% ETP, Due 10/1/15)		3,000		2,911		2,911
Supernus Pharmaceuticals, Inc. (2)(5)	Biotechnology	Term Loan (11.00% cash, 3.00% ETP, Due 8/1/14)		2,090		2,079		2,079
		Term Loan (11.00% cash, 2.50% ETP, Due 1/1/15)		5,962		5,915		5,915
Xcovery Holding Company, LLC (2)	Biotechnology	Term Loan (12.50% cash, Due 8/1/15)		918		915		915
		Term Loan (12.50% cash, Due 8/1/15)		1,444		1,439		1,439
		Term Loan (12.50% cash, Due 10/1/15)		250		249		249
Direct Flow Medical, Inc. (2)	Medical Device	Term Loan (11.00% cash, 3.00% ETP, Due 7/1/16)		5,000		4,831		4,831
Mitralign, Inc. (2)	Medical Device	Term Loan (12.00% cash, 3.00% ETP, Due 10/1/15)		1,714		1,655		1,655
		Term Loan (10.88% cash, 3.00% ETP, Due 11/1/15)		1,143		1,119		1,119
OraMetrix, Inc. (2)	Medical Device	Term Loan (11.50% cash, 3.00% ETP, Due 4/1/14)		2,468		1,966		1,966
		Revolver (11.50% (Prime + 8.25%) cash, Due 12/1/15)		2,000		2,449		2,449
PixelOptics, Inc. (2)	Medical Device	Term Loan (10.75% cash, 3.00% ETP, Due 11/1/14)		7,900		7,865		7,865
Tengion, Inc. (2)(5)	Medical Device	Term Loan (13.00% cash, Due 5/1/14)		3,660		3,560		3,560
Total Debt Investments — Life Science						62,599		61,464
Debt Investments — Technology — 72.9% (9)
Avalanche Technology, Inc. (2)	Semiconductors	Term Loan (10.00% cash, 2.00% ETP, Due 7/1/16)		4,000		3,866		3,866
Luxtera, Inc. (2)	Semiconductors	Term Loan (10.25% cash, 8.00% ETP, Due 12/1/15)		3,333		3,290		3,290
		Term Loan (10.25% cash, 8.00% ETP, Due 3/1/16)		1,667		1,642		1,642
Newport Media, Inc. (2)	Semiconductors	Term Loan (11.00% cash, 2.14% ETP, Due 1/1/16)		3,500		3,445		3,445
		Term Loan (11.00% cash, 2.14% ETP, Due 1/1/16)		3,500		3,445		3,445
Xtera Communications, Inc. (2)	Semiconductors	Term Loan (11.50% cash, Due 12/1/14)		8,222		8,136		8,136
		Term Loan (11.50% cash, Due 7/1/15)		2,000		1,972		1,972
Grab Networks, Inc. (2)	Internet and Media	Term Loan (12.00% cash, Due 1/1/16)		2,500		2,387		2,387
Optaros, Inc. (2)	Internet and Media	Term Loan (11.95% cash, 3.00% ETP, Due 10/1/15)		2,000		1,976		1,976
		Term Loan (11.95% cash, 3.00% ETP, Due 3/1/16)		500		495		495
SimpleTuition, Inc. (2)	Internet and Media	Term Loan (11.75% cash, Due 3/1/16)		5,000		4,905		4,905
Construction Software Technologies, Inc. (2)	Software	Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)		4,200		4,156		4,156
		Term Loan (11.75% cash, 5.00% ETP, Due 10/1/16)		4,200		4,156		4,156
Courion Corporation (2)	Software	Term Loan (11.45% cash, Due 10/1/15)		3,500		3,481		3,481
		Term Loan (11.45% cash, Due 10/1/15)		3,500		3,481		3,481
Fiberlink Communications Corporation (2)	Software	Term Loan (11.50% cash, 5.00% ETP, Due 7/1/16)		5,000		4,920		4,920
Kontera Technologies, Inc. (2)	Software	Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)		4,000		3,917		3,917
		Term Loan (11.50% cash, 3.00% ETP, Due 10/1/16)		4,000		3,917		3,917
Netuitive, Inc. (2)	Software	Term Loan (11.75% cash, Due 1/1/16)		3,000		2,939		2,939
Seapass Solutions, Inc. (2)	Software	Term Loan (11.65% cash, 4.00% ETP, Due 5/1/16)		5,000		4,933		4,933
		Term Loan (11.65% cash, 4.00% ETP, Due 5/1/16)		5,000		4,933		4,933
StreamBase Systems, Inc. (2)	Software	Term Loan (12.51% cash, Due 11/1/13)		1,360		1,353		1,353
		Term Loan (12.50% cash, Due 6/1/14)		558		553		553
		Term Loan (12.50% cash, Due 12/1/15)		1,500		1,477		1,477
Sys-Tech Solutions, Inc. (2)	Software	Term Loan (11.65% cash, Due 6/1/16)		7,500		7,193		7,193
Vidsys, Inc. (2)	Software	Term Loan (11.00% cash, 5.00% ETP, Due 6/1/16)		3,000		2,948		2,948
Aquion Energy, Inc. (2)	Power Management	Term Loan (10.25% cash, 4.00% ETP, Due 3/1/16)		3,333		3,312		3,312
		Term Loan (10.25% cash, 4.00% ETP, Due 3/1/16)		3,333		3,312		3,312
		Term Loan (10.25% cash, 4.00% ETP, Due 6/1/16)		3,333		3,309		3,309
Xtreme Power, Inc. (2)	Power Management	Term Loan (10.75% cash, 3.50% ETP, Due 5/1/16)		6,000		5,859		5,859
Total Debt Investments — Technology						105,708		105,708

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2012

(In thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount		Investments (6)		Value
Debt Investments — Cleantech — 16.4% (9)
Renmatix, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)		2,500		2,402		2,402
		Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16)		2,500		2,473		2,473
Semprius, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, 2.50% ETP, Due 6/1/16)		3,750		3,712		3,712
Cereplast, Inc. (5)(8)	Waste Recycling	Term Loan (12.00% cash, Due 8/1/14)		1,683		1,515		890
		Term Loan (12.00% cash, Due 8/1/14)		1,806		1,787		1,116
		Term Loan (15.00% cash, Due 4/4/13)		75		75		47
		Term Loan (15.00% cash, Due 4/4/13)		125		125		78
Aurora Algae, Inc. (2)	Energy Efficiency	Term Loan (10.50% cash, 2.00% ETP, Due 5/1/15)		2,075		2,062		2,062
Satcon Technology Corporation (5)(8)	Energy Efficiency	Term Loan (12.58% cash, Due 1/1/14)		5,278		5,278		—
Solarbridge Technologies, Inc. (2)	Energy Efficiency	Term Loan (11.65% cash, Due 4/1/16)		7,000		6,826		6,826
Tigo Energy, Inc. (2)	Energy Efficiency	Term Loan (11.00% cash, Due 8/1/14)		2,326		2,306		2,306
		Revolver (10.75% (Prime + 7.50%) cash, Due 1/1/14)		1,859		1,821		1,821
Total Debt Investments — Cleantech						30,382		23,733
Debt Investments — Healthcare information and services — 20.3% (9)
Accumetrics, Inc. (2)	Diagnostics	Term Loan (10.90% cash, 5.00% ETP, Due 6/1/16)		4,000		3,853		3,853
BioScale, Inc. (2)	Diagnostics	Term Loan (11.51% cash, Due 1/1/14)		2,643		2,630		2,630
Radisphere National Radiology Group, Inc. (2)	Diagnostics	Revolver (11.25% (Prime + 8.00%) cash, Due 10/1/15)		15,000		14,856		14,856
Recondo Technology, Inc. (2)	Software	Term Loan (11.50% cash, 3.00% ETP, Due 4/1/15)		2,000		1,968		1,968
		Term Loan (11.00% cash, 3.00% ETP, Due 1/1/17)		2,500		2,460		2,460
		Revolver (10.50% (Prime + 7.25%) cash, Due 4/1/15)		1,000		968		968
Singulex, Inc.	Other Healthcare	Term Loan (11.00% cash, 3.00% ETP, Due 3/1/14)		1,602		1,593		1,593
		Term Loan (11.00% cash, 3.00% ETP, Due 3/1/14)		1,068		1,064		1,064
Total Debt Investments — Healthcare information and services						29,392		29,392
Total Debt Investments						228,081		220,297
Warrant Investments — 3.8% (9)
Warrants — Life Science — 1.1% (9)
ACT Biotech Corporation	Biotechnology	1,390,910 Preferred Stock Warrants		—		83		—
Ambit Biosciences, Inc. (2)	Biotechnology	1,075,083 Preferred Stock Warrants		—		143		101
Anacor Pharmaceuticals, Inc. (2)(5)	Biotechnology	84,583 Common Stock Warrants		—		93		41
Anesiva, Inc.	Biotechnology	198,898 Common Stock Warrants		—		18		—
Celsion Corporation (2)(5)	Biotechnology	25,685 Common Stock Warrants		—		15		136
N30 Pharmaceuticals, LLC (2)	Biotechnology	214,200 Preferred Stock Warrants		—		122		252
Novalar Pharmaceuticals, Inc.	Biotechnology	84,845 Preferred Stock Warrants		—		69		—
Revance Therapeutics, Inc.	Biotechnology	199,470 Preferred Stock Warrants		—		224		404
Sample6 Technologies, Inc. (2)	Biotechnology	200,582 Preferred Stock Warrants		—		27		28
Sunesis Pharmaceuticals, Inc. (2)(5)	Biotechnology	116,203 Common Stock Warrants		—		83		251
Supernus Pharmaceuticals, Inc. (2)(5)	Biotechnology	42,083 Preferred Stock Warrants		—		94		117
Tranzyme, Inc. (2)(5)	Biotechnology	77,902 Common Stock Warrants		—		6		—
Direct Flow Medical, Inc. (2)	Medical Device	176,922 Preferred Stock Warrants		—		145		145
EnteroMedics, Inc. (5)	Medical Device	141,026 Common Stock Warrants		—		347		2
Mitralign, Inc. (2)	Medical Device	295,238 Common Stock Warrants		—		49		43
OraMetrix, Inc. (2)	Medical Device	812,348 Preferred Stock Warrants		—		78		—
PixelOptics, Inc. (2)	Medical Device	381,612 Preferred Stock Warrants		—		96		35
Tengion, Inc. (2)(5)	Medical Device	1,716,339 Common Stock Warrants		—		124		62
ViOptix, Inc.	Medical Device	375,763 Preferred Stock Warrants		—		13		—
Total Warrants — Life Science						1,829		1,617
Warrants — Technology — 1.9% (9)
OpenPeak, Inc.	Communications	18,997 Preferred Stock Warrants		—		89		—
Everyday Health, Inc.	Consumer-related Technologies	65,674 Preferred Stock Warrants		—		69		97
SnagAJob.com, Inc.	Consumer-related Technologies	365,396 Preferred Stock Warrants		—		23		269
Tagged, Inc.	Consumer-related Technologies	190,868 Preferred Stock Warrants		—		27		80
Avalanche Technology, Inc. (2)	Semiconductors	201,835 Preferred Stock Warrants		—		45		46
Impinj, Inc.	Semi-conductor	1 Preferred Stock Warrants		—		7		—
Luxtera, Inc. (2)	Semiconductors	1,827,485 Preferred Stock Warrants		—		34		30
Newport Media, Inc. (2)	Semiconductors	188,764 Preferred Stock Warrants		—		40		40
Xtera Communications, Inc. (2)	Semiconductors	983,607 Preferred Stock Warrants		—		206		1

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2012

(In thousands)

			Principal		Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount		Investments (6)		Value
XIOtech, Inc.	Data Storage	2,217,979 Preferred Stock Warrants		—		22		20
Cartera Commerce, Inc.	Internet and media	90,909 Preferred Stock Warrants		—		16		162
Grab Networks, Inc. (2)	Internet and media	1,493,681 Preferred Stock Warrants		—		194		119
Optaros, Inc. (2)	Internet and media	477,403 Preferred Stock Warrants		—		20		18
SimpleTuition, Inc. (2)	Internet and media	189,573 Preferred Stock Warrants		—		63		56
IntelePeer, Inc.	Networking	141,549 Preferred Stock Warrants		—		39		481
Motion Computing, Inc.	Networking	260,707 Preferred Stock Warrants		—		7		293
Clarabridge, Inc.	Software	104,503 Preferred Stock Warrants		—		28		17
Construction Software Technologies, Inc. (2)	Software	386,415 Preferred Stock Warrants		—		69		49
Courion Corporation (2)	Software	772,543 Preferred Stock Warrants		—		107		98
DriveCam, Inc.	Software	71,639 Preferred Stock Warrants		—		19		120
Kontera Technologies, Inc. (2)	Software	99,476 Preferred Stock Warrants		—		101		101
Netuitive, Inc. (2)	Software	748,453 Preferred Stock Warrants		—		75		61
Seapass Solutions, Inc. (2)	Software	202,892 Preferred Stock Warrants		—		113		105
StreamBase Systems, Inc. (2)	Software	306,041 Preferred Stock Warrants		—		83		63
Sys-Tech Solutions, Inc. (2)	Software	375,000 Preferred Stock Warrants		—		242		242
Vidsys, Inc. (2)	Software	178,802 Preferred Stock Warrants		—		23		23
Aquion Energy, Inc. (2)	Power Management	82,644 Preferred Stock Warrants		—		7		4
Xtreme Power, Inc. (2)	Power Management	182,723 Preferred Stock Warrants		—		76		68
Total Warrants — Technology						1,844		2,663
Warrants — Cleantech — 0.2% (9)
Renmatix, Inc. (2)	Alternative Energy	52,296 Preferred Stock Warrants		—		69		70
Semprius, Inc. (2)	Alternative Energy	519,981 Preferred Stock Warrants		—		25		27
Cereplast, Inc. (5)	Waste Recycling	365,000 Common Stock Warrants		—		175		2
Enphase Energy, Inc. (5)	Energy Efficiency	161,959 Common Stock Warrants		—		176		4
Satcon Technology Corporation (5)	Energy Efficiency	493,097 Common Stock Warrants		—		285		—
Solarbridge Technologies, Inc. (2)	Energy Efficiency	1,761,051 Preferred Stock Warrants		—		125		112
Tigo Energy, Inc. (2)	Energy Efficiency	190,901 Preferred Stock Warrants		—		101		72
Total Warrants — Cleantech						956		287
Warrants — Healthcare information and services — 0.6% (9)
Accumetrics, Inc. (2)	Diagnostics	1,028,57 Preferred Stock Warrants		—		107		107
BioScale, Inc. (2)	Diagnostics	315,618 Preferred Stock Warrants		—		55		46
Precision Therapeutics, Inc.	Diagnostics	561,409 Preferred Stock Warrants		—		73		142
Radisphere National Radiology Group, Inc. (2)	Diagnostics	519,943 Preferred Stock Warrants		—		378		288
Recondo Technology, Inc. (2)	Software	360,645 Preferred Stock Warrants		—		60		144
Patientkeeper, Inc.	Other Healthcare	396,410 Preferred Stock Warrants		—		269		31
Singulex, Inc.	Other Healthcare	293,632 Preferred Stock Warrants		—		44		71
Talyst, Inc.	Other Healthcare	300,360 Preferred Stock Warrants		—		100		72
Total Warrants — Healthcare information and services						1,086		901
Total Warrants						5,715		5,468
Other Investments — 1.4% (9)
Vette Technology, LLC	Data Storage	Royalty Agreement Due 4/18/2019				4,880		2,100
Total Other Investments						4,880		2,100
Equity — 0.5% (9)
Insmed Incorporated (5)	Biotechnology	33,208 Common Stock				227		222
Overture Networks Inc.	Communications	386,191 Preferred Stock				482		526
Total Equity						709		748
Total Portfolio Investment Assets — 157.7% (9)					$	239,385	$	228,613

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments (Unaudited)

December 31, 2012

(In thousands)

			Principal	Cost of		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)	Amount	Investments (6)		Value
Short Term Investments — Money Market Funds — 1.8% (9)
Blackrock Liquid Fed Funds Institutional (Fund #30)				$	2,197	$	2,197
Fidelity Prime Money Market (Class I Fund #690)					91		91
US Bank Money Market					272		272
Total Short Term Investments — Money Market Funds				$	2,560	$	2,560

(1)

All of the Company’s investments are in entities which are domiciled in the United States and/or have a principal place of business in the United States.

(2)

Has been pledged as collateral under the Credit Facilities.

(3)

All investments are less than 5% ownership of the class and ownership of the portfolio company.

(4)

(5)

Portfolio company is a public company.

(6)

For debt investments, represents principal balance less unearned income.

(7)

Preferred and common stock warrants, equity interests and other investments are non-income producing.

(8)

Debt is on non-accrual status at December 31, 2012 and is, therefore, considered non-income producing.

(9)

Value as a percent of net assets.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Note 1. Organization

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“1940 Act”). In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined in Subtitle A, Chapter 1, under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is not subject to federal income tax on the portion of its taxable income and capital gains the Company distributes to the stockholders. The Company primarily makes secured loans to development-stage companies in the technology, life science, healthcare information and services and cleantech industries. Substantially all of the Company’s debt investments consisting of loans are secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the NASDAQ Global Select Market under the symbol “HRZN.” The Company was formed to continue and expand the business of Compass Horizon Funding Company LLC (“CHF”), a Delaware limited liability company, which commenced operations in March 2008 and became the Company’s wholly owned subsidiary with the completion of the IPO.

Horizon Credit I LLC (“Credit I”) was formed as a Delaware limited liability company on January 23, 2008, with CHF as the sole equity member. Credit I is a special purpose bankruptcy remote entity and is a separate legal entity from the Company and CHF. There has been no activity in Credit I during the nine months ended September 30, 2013.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as the sole equity member. Credit II is a special purpose bankruptcy remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

Horizon Credit III LLC (“Credit III”) was formed as a Delaware limited liability company on May 30, 2012, with the Company as the sole equity member. Credit III is a special purpose bankruptcy remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit III are not available to creditors of the Company or any other entity other than Credit III’s lenders.

Longview SBIC GP LLC and Longview SBIC LP (collectively, “Horizon SBIC”) were formed as a Delaware limited liability company and Delaware limited partnership, respectively, on February 11, 2011. Horizon SBIC are wholly owned subsidiaries of the Company and were formed in anticipation of obtaining a license to operate a small business investment company from the U. S. Small Business Administration. There has been no activity in Horizon SBIC since its inception.

The Company formed Horizon Funding 2013-1 LLC (“2013-1 LLC”) as a Delaware limited liability company on June 7, 2013 and Horizon Funding Trust 2013-1 (“2013-1 Trust” and, together with the 2013-1 LLC, the “2013-1 Entities”) as a Delaware trust on June 18, 2013. The 2013-1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2013-1 Entities for purposes of securitizing $189.3 million of secured loans and issuing fixed-rate asset-backed notes in an aggregate principal amount of $90 million (the “Asset-Backed Notes”).

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments made and the capital appreciation from the warrants received when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”), under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Note 2. Basis of Presentation and Significant Accounting Policies

Basis of Financial Statement Presentation

The accompanying consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10-Q and Articles 6 or 10 of Regulation S-X. In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and related notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2012.

Principles of Consolidation

As permitted under Regulation S-X and the AICPA Audit and Accounting Guide for Investment Companies, the Company will generally not consolidate its investment in a company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s subsidiaries in its consolidated financial statements.

Use of Estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair Value

The Company measures substantially all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 5. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

In May 2011, the FASB issued Accounting Standards Update (ASU) 2011-04, Amendments to Achieve Common Fair Value Measurements and Disclosure Requirements in U.S. GAAP and IFRSs, (ASU 2011-04). ASU 2011-04 converges the fair value measurement guidance in U.S. GAAP and IFRSs. Some of the amendments clarify the application of existing fair value measurement requirements, while other amendments change a particular principle in existing guidance. In addition, ASU 2011-04 requires additional fair value disclosures. The Company has adopted ASU 2011-04 and included additional disclosures in Note 5.

See Note 5 for additional information regarding fair value.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and cleantech industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments

Investments are recorded at fair value. The Company’s board of directors (the “Board”) determines the fair value of its portfolio investments. The Company intends to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a loan becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the loan is placed on non-accrual status and the recognition of interest income is discontinued. Interest payments received on loans that are on non-accrual status are treated as reductions of principal until the principal is repaid. As of September 30, 2013, there were three investments on non-accrual status with a cost of $11.1 million and a fair value of $7.1 million. As of December 31, 2012, there were three investments on non-accrual status with a cost of $12.9 million and a fair value of $4.9 million.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Loan origination fees, net of certain direct origination costs, are deferred, and along with unearned income, are amortized as a level yield adjustment over the respective term of the loan. Fees for counterparty loan commitments with multiple loans are allocated to each loan based upon each loan’s relative fair value. When a loan is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the loan is returned to accrual status.

Certain loan agreements also require the borrower to make an end-of-term payment (“ETP”), which is accrued into interest income over the life of the loan to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay all principal and interest due.

In connection with substantially all of the Company’s lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are also recorded as unearned loan income on the grant date. The unearned income is recognized as interest income over the contractual life of the related loan in accordance with the Company’s income recognition policy. Subsequent to loan origination, the warrants are also measured at fair value using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized gain or loss on investments. Gains or losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains or losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of our portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation, when gains or losses are realized.

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. Debt issuance costs are recognized as assets and are amortized as interest expense over the term of the related credit facility. The unamortized balance of debt issuance costs as of September 30, 2013 and December 31, 2012, included in other assets, was $4.9 million and $3.7 million, respectively. The accumulated amortization balance of debt issuance cost as of September 30, 2013 and December 31, 2012 was $1.5 million and $0.6 million, respectively. The amortization expense for the nine months ended September 30, 2013 and 2012 was $0.9 and $0.3 million, respectively.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Income Taxes

The Company elected to be treated as a RIC under subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC, among other things, the Company is required to meet certain source of income and asset diversification requirements and timely distribute to its stockholders at least 90% of investment company taxable income, as defined by the Code, for each year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which will generally relieve the Company from U.S. federal income taxes.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year dividend distributions into the next tax year and pay a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year dividend distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the nine months ended September 30, 2013, $0.2 million was recorded for U.S. federal excise tax. For the nine months ended September 30, 2012, no amount was recorded for U.S. federal excise tax.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. There were no material uncertain tax positions at September 30, 2013 and December 31, 2012. The 2012, 2011 and 2010 tax years remain subject to examination by U.S. federal and state tax authorities.

Dividends

Dividends to common stockholders are recorded on the declaration date. The amount to be paid out as a dividend is determined by the Board. Net realized long-term capital gains, if any, are distributed at least annually, although the Company may decide to retain such capital gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions and other distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board authorizes, and the Company declares, a cash dividend, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash dividends automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash dividend. The Company may use newly issued shares to implement the plan (especially if the Company’s shares are trading at a premium to net asset value), or the Company may purchase shares in the open market in connection with the obligations under the plan.

Transfers of Financial Assets

Assets related to transactions that do not meet ASC Topic 860 — Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s consolidated statements of financial condition as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Transfers of financial assets are accounted for as sales, when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets, and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Note 3. Related Party Transactions

Investment Management Agreement

On October 28, 2010, the Company entered into the Investment Management Agreement with the Advisor, which was renewed by the Board in August 2013, under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the U.S. Securities and Exchange Commission. The Advisor receives fees for providing services, consisting of two components, a base management fee and an incentive fee.

The base management fee under the Investment Management Agreement is calculated at an annual rate of 2.00% of the Company’s gross assets, payable monthly in arrears. For purposes of calculating the base management fee, the term “gross assets” includes any assets acquired with the proceeds of leverage. The management fee payable at September 30, 2013 and December 31, 2012 was $0.3 million and $0.4 million, respectively. The base management fee expense was $1.3 million and $1.1 million for the three months ended September 30, 2013 and 2012, respectively. The base management fee expense was $3.8 million and $3.0 million for the nine months ended September 30, 2013 and 2012, respectively.

The incentive fee has two parts, as follows:

The first part is calculated and payable quarterly in arrears based on the Company’s pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, pre-incentive fee net investment income means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus operating expenses for the quarter (including the base management fee, expenses payable under the administration agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-incentive fee net investment income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with payment-in-kind interest and zero coupon securities), accrued income that the Company has not yet received in cash. The incentive fee with respect to the pre-incentive fee net income is 20.00% of the amount, if any, by which the pre-incentive fee net investment income for the immediately preceding calendar quarter exceeds a 1.75% (which is 7.00% annualized) hurdle rate and a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the net investment income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the pre-incentive fee net investment income with respect to that portion of such pre-incentive fee net investment income, if any, that exceeds the hurdle rate but is less than 2.1875%. The effect of this provision is that, if pre-incentive fee net investment income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the pre-incentive fee net investment income as if a hurdle rate did not apply.

Pre-incentive fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives pre-incentive fee net investment income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s aggregate realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee.

The performance based incentive fee expense was $0.9 million and $0.7 million for the three months ended September 30, 2013 and 2012, respectively. The performance based incentive fee expense was $2.5 million and $2.0 million for the nine months ended September 30, 2013 and 2012, respectively. The entire performance based incentive fee expense for both the three and nine months ended September 30, 2013 and 2012, represents part one of the incentive fee. The incentive fee payable for both September 30, 2013 and December 31, 2012 was $0.9 million. The entire incentive fee payable as of September 30, 2013 and December 31, 2012 represents part one of the incentive fee.

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s chief compliance officer and chief financial officer and their respective staffs. For the three months ended September 30, 2013 and 2012, $0.3 million and $0.4 million were charged to operations under the Administration Agreement, respectively. For both the nine months ended September 30, 2013 and 2012, $0.9 million was charged to operations under the Administration Agreement.

Note 4. Investments

Investments, all of which are with portfolio companies in the United States, consisted of the following:

	September 30, 2013				December 31, 2012
	Cost		Fair Value		Cost		Fair Value
Money market funds	$	25,019	$	25,019	$	2,560	$	2,560
Restricted investments	$	3,568	$	3,568	$	—	$	—
Non-affiliate investments
Debt	$	236,870	$	231,661	$	228,081	$	220,297
Warrants		5,683		6,611		5,715		5,468
Other Investments		4,760		2,000		4,880		2,100
Equity		782		1,047		709		748
Total non-affiliate investments	$	248,095	$	241,319	$	239,385	$	228,613

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

The following table shows the Company’s portfolio investments by industry sector:

	September 30, 2013				December 31, 2012
	Cost		Fair Value		Cost		Fair Value
Life Science
Biotechnology	$	25,074	$	25,073	$	40,358	$	39,569
Medical Device		22,475		19,609		24,296		23,733
Technology
Consumer-Related Technologies		118		436		118		445
Networking		46		304		46		774
Software		72,884		73,449		55,220		55,237
Data Storage		4,782		2,020		4,901		2,121
Internet and Media		6,679		6,770		10,056		10,118
Communications		6,956		6,805		571		526
Semiconductors		36,542		36,401		26,128		25,913
Power Management		15,182		14,409		15,875		15,864
Cleantech
Energy Efficiency		15,102		14,791		18,914		13,138
Waste Recycling		2,394		1,629		3,744		2,199
Alternative Energy		12,934		12,937		8,680		8,683
Healthcare Information and Services
Diagnostics		15,421		15,256		21,952		21,921
Other Healthcare Related Services		7,373		7,193		3,067		2,829
Software		4,133		4,237		5,459		5,543
Total non-affiliate investments	$	248,095	$	241,319	$	239,385	$	228,613

Note 5. Fair Value

The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1 Quoted prices in active markets for identical assets and liabilities.

Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Investments are valued at fair value as determined in good faith by the Board, based on input of management, the audit committee and independent valuation firms that have been engaged at the direction of the Board to assist in the valuation of each portfolio investment without a readily available market quotation at least once during a trailing twelve-month period under a valuation policy and a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with 25% (based on fair value) of the Company’s valuation of portfolio companies without readily available market quotations subject to review by an independent valuation firm.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money Market Funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt Investments: For variable rate debt investments which re-price frequently and have no significant change in credit risk, carrying values are a reasonable estimate of fair values. The fair value of fixed rate debt investments is estimated by discounting the expected future cash flows using the year end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. At both September 30, 2013 and December 31, 2012, the discount rates used ranged from 9% to 25%. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant Investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

•

Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

•

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on guideline publicly traded companies within indices similar in nature to the underlying company issuing the warrant. A total of seven such indices were used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value investment.

•

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

•

Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. Significant increases (decreases) in this unobservable input would result in significantly lower (higher) fair value measurement.

•

Historical portfolio experience on cancellations and exercises of warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or IPOs, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity Investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 with the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 with the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other Investments: Other investments will be valued based on the facts and circumstances of the underlying agreement. The Company currently values one contractual agreement using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized this other investment as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of investments as of September 30, 2013 and December 31, 2012. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy the Company may also use other valuation techniques and methodologies when determining fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements:

September 30, 2013
	Fair		Valuation Techniques/	Unobservable
Investment Type	Value		Methodologies	Input	Range
Debt investments	$	224,557	Discounted Expected Future Cash Flows	Hypothetical Market Yield	9% - 25%

		7,104	Multiple Probability Weighted Cash Flow Model	Discount Rate Probability Weighting	25%– 33% 0% - 65%

Warrant investments		5,296	Black-Scholes Valuation Model	Price per share Average Industry Volatility	$0.0 – $63.98 21%
				Marketability Discount	20%
				Estimated Time to Exit	1 to 10 years

Other investments		2,000	Multiple Probability Weighted Cash Flow Model	Discount Rate Probability Weighting	25% 10% - 45%

Equity investments		529	Most Recent Equity Investment	Price Per Share	$1.09 – 1.50
Total Level 3 investments	$	239,486

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

December 31, 2012
	Fair		Valuation Techniques/	Unobservable
Investment Type	Value		Methodologies	Input	Range
Debt investments	$	215,396	Discounted Expected Future Cash Flows	Hypothetical Market Yield	8% - 25%

		4,901	Multiple Probability Weighted Cash Flow Model	Discount Rate Probability Weighting	25% 10% - 60%

Warrant investments		4,914	Black-Scholes Valuation Model	Price per share Average Industry Volatility	$0.0 - $9.56 21%
				Marketability Discount	20%
				Estimated Time to Exit	1 to 10 years

Other investments		2,100	Multiple Probability Weighted Cash Flow Model	Discount Rate Probability Weighting	25% 10% - 45%

Equity investments		526	Market Comparable Companies	Revenue Multiple	1.5x – 2.0x
Total Level 3 investments	$	227,837

Borrowings: The carrying amount of borrowings under the Credit Facilities (as defined in Note 6) approximates fair value due to the variable interest rate of the Credit Facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed rate 2019 Notes (as defined in Note 6) is based on the closing public share price on the date of measurement. At September 30, 2013, the 2019 Notes were trading on the New York Stock Exchange for $25.42 per note, or $33.6 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on or around September 30, 2013, the Asset-Backed Notes (as defined in Note 6) were trading for $0.9930 per dollar at par value, or $89.4 million, and are categorized as Level 3 with the fair value hierarchy described above. These liabilities are not recorded at fair value on a recurring basis.

Off-Balance-Sheet Instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following tables detail the assets and liabilities that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	September 30, 2013
	Total		Level 1		Level 2		Level 3
Money market funds	$	25,019	$	—	$	25,019	$	—
Restricted investments	$	3,568	$	—	$	3,568	$	—
Debt investments	$	231,661	$	—	$	—	$	231,661
Warrant investments	$	6,611	$	—	$	1,315	$	5,296
Other investments	$	2,000	$	—	$	—	$	2,000
Equity investments	$	1,047	$	518	$	—	$	529

	December 31, 2012
	Total		Level 1		Level 2		Level 3
Money market funds	$	2,560	$	—	$	2,560	$	—
Debt investments	$	220,297	$	—	$	—	$	220,297
Warrant investments	$	5,468	$	—	$	554	$	4,914
Other investments	$	2,100	$	—	$	—	$	2,100
Equity investments	$	748	$	222	$	—	$	526

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

The following tables show a reconciliation of the beginning and ending balances for Level 3 assets for the three months ended September 30, 2013:

	Three Months Ended September 30, 2013
	Debt Investments			Warrant Investments			Equity Investments		Other Investments			Total
Level 3 assets, beginning of period	$	237,871		$	5,150		$	529	$	2,100		$	245,650
Purchase of investments		11,500			—			—		—			11,500
Warrants and equity received and classified as Level 3		—			200			—		—			200
Principal payments received on investments		(17,986	)		—			—		(33	)		(18,019	)
Unrealized appreciation (depreciation) included in earnings		4,844			216			—		(67	)		4,993
Realized loss included in earnings		(5,010	)		(270	)		—		—			(5,280	)
Other		442			—			—		—			442
Level 3 assets, end of period	$	231,661		$	5,296		$	529	$	2,000		$	239,486

During the three months ended September 30, 2013, there were no transfers between levels.

	Three Months Ended September 30, 2012
	Debt Investments			Warrant Investments		Equity Investments		Other Investments		Total
Level 3 assets, beginning of period	$	187,932		$	4,355	$	526	$	2,000	$	194,813
Purchase of investments		36,464			—		—		—		36,464
Warrants and equity received and classified as Level 3		—			397		—		—		397
Principal payments received on investments		(12,066	)		—		—		—		(12,066	)
Unrealized appreciation included in earnings		339			40		—		—		379
Other		(264	)		—		—		—		(264	)
Level 3 assets, end of period	$	212,405		$	4,792	$	526	$	2,000	$	219,723

During the three months ended September 30, 2012, there were no transfers between levels.

The following tables show a reconciliation of the beginning and ending balances for Level 3 assets for the nine months ended September 30, 2013:

	Nine Months Ended September 30, 2013
	Debt Investments			Warrant Investments			Equity Investments			Other Investments			Total
Level 3 assets, beginning of period	$	220,297		$	4,914		$	526		$	2,100		$	227,837
Purchase of investments		69,143			—			—			—			69,143
Warrants and equity received and classified as Level 3		—			626			—			—			626
Principal payments received on investments		(55,921	)		—			—			(33	)		(55,954	)
Proceeds from sale of warrants		—			(39	)		—			—			(39	)
Unrealized appreciation (depreciation) included in earnings		2,595			226			(70	)		(67	)		2,684
Realized loss included in earnings		(5,010	)		(315	)		—			—			(5,325	)
Transfer out of Level 3		—			(116	)		—			—			(116	)
Transfer from debt to equity investment		(73	)		—			73			—			—
Other		630			—			—			—			630
Level 3 assets, end of period	$	231,661		$	5,296		$	529		$	2,000		$	239,486

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

The Company’s transfers between levels are recognized at the end of the reporting period. During the nine months ended September 30, 2013, there were no transfers between Level 1 and Level 2. The transfer out of Level 3 relates to warrants held in one portfolio company, with a value of $0.1 million, that were transferred into Level 2 due to the portfolio company becoming a public company during the nine months ended September 30, 2013. Because warrants held in publicly traded companies are determined based on inputs that are readily available in public markets or can be derived from information available in public markets, the Company has categorized the warrants as Level 2 within the fair value hierarchy described above as of September 30, 2013.

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at September 30, 2013 includes $2.7 million unrealized depreciation on loans, $0.1 million unrealized appreciation on warrants, $0.1 million unrealized depreciation on equity and $0.1 million unrealized depreciation on other investments.

	Nine Months Ended September 30, 2012
	Debt Investments			Warrant Investments			Equity Investments		Other Investments		Total
Level 3 assets, beginning of period	$	173,286		$	4,048		$	526	$	—	$	177,860
Purchase of investments		86,720			—			—		—		86,720
Warrants and equity received and classified as Level 3		—			937			—		—		937
Principal payments received on investments		(44,186	)		—			—		—		(44,186	)
Unrealized (depreciation) appreciation included in earnings		(872	)		85			—		—		(787	)
Transfer out of Level 3		—			(278	)		—		—		(278	)
Transfer from debt to other investments		(2,000	)		—			—		2,000		—
Other		(543	)		—			—		—		(543	)
Level 3 assets, end of period	$	212,405		$	4,792		$	526	$	2,000	$	219,723

During the nine months ended September 30, 2012, there were no transfers between Level 1 and Level 2. The transfer out of Level 3 relates to warrants held in two portfolio companies, with a value of $0.3 million, that were transferred into Level 2 due to the portfolio company becoming a public company during the nine months ended September 30, 2012. Because the fair value of warrants held in publicly traded companies are determined based on inputs that are readily available in public markets or can be derived from information available in public markets, the Company has categorized these warrants as of September 30, 2012 as Level 2 within the fair value hierarchy described above.

The Company discloses fair value information about financial instruments, whether or not recognized in the statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of September 30, 2013 and December 31, 2012, the recorded book balances equaled fair values of all the Company’s financial instruments, except for the Company’s 2019 Notes and Asset-Backed Notes, as previously described.

Off-balance-sheet instruments

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the Company expects the fair values of its financial instruments to change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new loans and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Note 6. Borrowings

A summary of the Company’s borrowings as of September 30, 2013 and December 31, 2012 is as follows:

	September 30, 2013
	Total Commitment		Balance Outstanding		Unused Commitment
Asset-Backed Notes	$	90,000	$	90,000	$	—
Wells Facility		75,000		—		75,000
Fortress Facility		75,000		10,000		65,000
2019 Notes		33,000		33,000		—
Total	$	273,000	$	133,000	$	140,000

	December 31, 2012
	Total Commitment		Balance Outstanding		Unused Commitment
Wells Facility	$	75,000	$	46,020	$	28,980
Fortress Facility		75,000		10,000		65,000
2019 Notes		33,000		33,000		—
Total	$	183,000	$	89,020	$	93,980

In accordance with the 1940 Act, with certain limited exceptions, the Company is only allowed to borrow amounts such that the asset coverage, as defined in the 1940 Act, is at least 200% after such borrowings. As of September 30, 2013, the asset coverage for borrowed amounts was 208%.

The Company entered into a revolving credit facility (the “Wells Facility”) with Wells Fargo Capital Finance, LLC (“Wells”) effective July 14, 2011. The Wells Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the current $75 million commitment provided by Wells. The Wells Facility is collateralized by all loans and warrants held by Credit II and permits an advance rate of up to 50% of eligible loans held by Credit II. The Wells Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the loans securing the Wells Facility to certain criteria for qualified loans and includes portfolio company concentration limits as defined in the related loan agreement. The Wells Facility has a three-year revolving term followed by a three-year amortization period and matures on July 14, 2017. The interest rate was based upon the one-month LIBOR plus a spread of 4.00%, with a LIBOR floor of 1.00%. On May 28, 2013, the Company and Wells amended the Wells Facility. As amended, effective May 1, 2013, the stated interest rate was reduced to one-month LIBOR plus a spread of 3.25%, with a LIBOR floor of 1.00%. In general, all other terms and conditions of the Wells Facility remain unchanged. The rate at September 30, 2013 and December 31, 2012 was 4.25% and 5.0%, respectively. The average rate for the three months ended September 30, 2013 and 2012 was 4.25% and 5.0%, respectively. There were no amounts drawn on the Wells Facility during the three months ended September 30, 2013. The average rate for the nine months ended September 30, 2013 and 2012 was 4.8% and 5.0%, respectively. The average amount of borrowings were $9.9 million for the three months ended September 30, 2012. The average amounts of borrowings were $35.0 million and $11.7 million for the nine months ended September 30, 2013 and 2012, respectively.

On March 23, 2012, the Company issued and sold an aggregate principal amount of $30 million of 7.375% senior unsecured notes due in 2019, and, on April 18, 2012, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $3 million of such notes (collectively, the “2019 Notes”). The 2019 Notes will mature on March 15, 2019 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 15, 2015 at a redemption price of $25 per security plus accrued and unpaid interest. The 2019 Notes bear interest at a rate of 7.375% per year payable quarterly on March 15, June 15, September 15 and December 15 of each year. The 2019 Notes are the Company’s direct unsecured obligations and (i) rank equally with the Company’s future senior unsecured indebtedness; (ii) rank senior to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2019 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security) to the extent of the value of the assets securing such indebtedness and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of September 30, 2013, the Company was in material compliance with the terms of the 2019 Notes. The 2019 Notes are listed on the New York Stock Exchange under the symbol “HTF.”

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

The Company entered into a term loan credit facility (the “Fortress Facility” and, together with the Wells Facility, the “Credit Facilities”) with Fortress Credit Co LLC effective August 23, 2012. The Fortress Facility is collateralized by all loans and warrants held by Credit III. The Fortress Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the loans securing the Fortress Facility to certain criteria for qualified loans and includes portfolio company concentration limits as defined in the related loan agreement. The Fortress Facility, among other things, has a three-year term subject to two one-year extensions with a draw period of up to four years. The Fortress Facility requires the payment of an unused line fee in an amount equal to 1.00% of any unborrowed amount available under the facility annually and has an effective advance rate of 66% against eligible loans. The Fortress Facility generally bears interest based upon the one-month LIBOR plus a spread of 6.00%, with a LIBOR floor of 1.00%. The rate at both September 30, 2013 and December 31, 2012 was 7.00%, and the average rate for both the three and nine months ended September 30, 2013 was 7.00%. The average amount of borrowings was $10.0 million for both the three and nine months ended September 30, 2013.

On June 28, 2013, the Company completed a $189.3 million securitization of secured loans which it originated. 2013-1 Trust, a newly formed wholly owned subsidiary of the Company, issued $90 million in aggregate principal amount of fixed-rate asset-backed notes (the “Asset-Backed Notes”), which are rated A2(sf) by Moody’s Investors Service, Inc. The Company is the sponsor, originator and servicer for the transaction. The Asset-Backed Notes bear interest at a fixed rate of 3.00% per annum and have a stated maturity of May 15, 2018.

The Asset-Backed Notes were issued by 2013-1 Trust pursuant to a Note Purchase Agreement (the “Note Purchase Agreement”), dated as of June 28, 2013, by and among the Company, 2013-1 LLC, as trust depositor, 2013-1 Trust and Guggenheim Securities, LLC (“Guggenheim Securities”), as initial purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of such portfolio companies. The pool of loans is to be serviced by the Company. In connection with the issuance and sale of the Asset-Backed Notes, the Company has made customary representations, warranties and covenants in the Note Purchase Agreement. The Asset-Backed Notes are secured obligations of 2013-1 Trust and are non-recourse to the Company.

As part of the transaction, the Company entered into a Sale and Contribution Agreement, dated as of June 28, 2013 (the “Sale and Contribution Agreement”), with 2013-1 LLC pursuant to which the Company has agreed to sell or has contributed to 2013-1 LLC certain secured loans made to certain portfolio companies of the Company (the “Loans”). The Company has made customary representations, warranties and covenants in the Sale and Contribution Agreement with respect to the Loans as of the date of the transfer of the Loans to 2013-1 LLC. The Company has also entered into a sale and servicing agreement, dated as of June 28, 2013, with 2013-1 LLC and 2013-1 Trust pursuant to which 2013-1 LLC has agreed to sell or has contributed the Loans to 2013-1 Trust. The Company has made customary representations, warranties and covenants in the sale and servicing agreement. The Company will also serve as administrator to 2013-1 Trust pursuant to an administration agreement, dated as of June 28, 2013, with 2013-1 Trust, Wilmington Trust, National Association, and U.S. Bank National Association. 2013-1 Trust also entered into an indenture, dated as of June 28, 2013, which governs the Asset-Backed Notes and includes customary covenants and events of default. In addition, 2013-1 LLC entered into an amended and restated trust agreement, dated as of June 28, 2013, which includes customary representations, warranties and covenants. The Asset-Backed Notes were sold through an unregistered private placement to “qualified institutional buyers” in compliance with the exemption from registration provided by Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to institutional “accredited investors” (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) who, in each case, are “qualified purchasers” for purposes of Section 3(c)(7) under the 1940 Act.

On June 3, 2013, the Company and Guggenheim Securities entered into a Promissory Note (the “Promissory Note”) whereby Guggenheim Securities made a term loan in the original principal amount of $15 million (the “Term Loan”) to the Company. The Company granted Guggenheim Securities a security interest in all of its assets to secure the Term Loan. On June 28, 2013, the Company used a portion of the proceeds of the private placement of the Asset-Backed Notes to repay all of its outstanding obligations under the Term Loan and the security interest of Guggenheim Securities was released.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Under the terms of the Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through principal collections from the underlying securitized debt portfolio, which may be used to make monthly interest and principal payments on the Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds on the Consolidated Statement of Assets and Liabilities. There was $3.6 million of restricted investments in money market funds as of September 30, 2013.

Note 7. Financial Instruments with Off-Balance-Sheet Risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $7.3 million and $24.6 million as of September 30, 2013 and December 31, 2012, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, such as revolving credit arrangements or similar transactions. Commitments may also include a financial or non-financial milestone that has to be achieved before the commitment can be drawn. Commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements.

Note 8. Concentrations of Credit Risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and cleantech industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The largest loans may vary from year to year as new loans are recorded and repaid. The Company’s five largest loans represented 21% and 23% of total loans outstanding as of September 30, 2013 and December 31, 2012, respectively. No single loan represents more than 10% of the total loans as of September 30, 2013 and December 31, 2012. Loan income, consisting of interest and fees, can fluctuate significantly upon repayment of large loans. Interest income from the five largest loans accounted for 21% and 23% of total interest income on investments for the three months ended September 30, 2013 and 2012, respectively. Interest income from the five largest loans accounted for 22% and 23% of total interest income on investments for the nine months ended September 30, 2013 and 2012, respectively.

Horizon Technology Finance Corporation and Subsidiaries

Notes to Consolidated Financial Statements

(In thousands, except shares and per share data)

Note 9. Dividends and Distributions

The Company’s dividends and distributions are recorded on the record date. The following table summarizes the Company’s dividend declaration and distribution activity since inception:

Date Declared	Record Date	Payment Date	Amount Per Share		Cash Distribution		DRIP Shares Issued		DRIP Share Value
Nine Months Ended September 30, 2013
8/2/13	11/19/13	12/16/13	$	0.115	$	—		—	$	—
8/2/13	10/17/13	11/15/13	$	0.115	$	—		—	$	—
8/2/13	9/18/13	10/15/13	$	0.115	$	1,051		3,882	$	52
5/3/13	8/19/13	9/16/13	$	0.115	$	1,057		3,376	$	46
5/3/13	7/17/13	8/15/13	$	0.115	$	1,060		2,980	$	42
5/3/13	6/20/13	7/15/13	$	0.115	$	1,070		2,191	$	31
3/8/13	5/20/13	6/17/13	$	0.115	$	1,086		1,099	$	15
3/8/13	4/18/13	5/15/13	$	0.115	$	1,087		1,035	$	15
3/8/13	3/20/13	4/15/13	$	0.115	$	1,046		3,867	$	55
			$	1.035	$	7,457		18,430	$	256
Year Ended December 31, 2012
11/27/12	2/21/13	3/15/13	$	0.115	$	1,050		3,392	$	50
11/27/12	1/18/13	2/15/13	$	0.115	$	1,087		898	$	14
11/27/12	12/20/12	1/15/13	$	0.115	$	1,056		2,930	$	44
11/2/12	11/16/12	11/30/12	$	0.450	$	4,243		4,269	$	61
8/7/12	8/17/12	8/31/12	$	0.450	$	4,105		11,608	$	193
5/3/12	5/17/12	5/31/12	$	0.450	$	3,402		2,299	$	37
3/12/12	3/23/12	3/30/12	$	0.450	$	3,378		3,517	$	58
			$	2.145	$	18,321		28,913	$	457
Year Ended December 31, 2011
11/8/11	11/23/11	11/30/11	$	0.450	$	3,281		9,814	$	151
8/9/11	8/23/11	8/30/11	$	0.400	$	2,836		13,193	$